{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:31:43Z","timestamp":1774438303653,"version":"3.50.1"},"reference-count":42,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Computational and Mathematical Methods in Medicine"],"published-print":{"date-parts":[[2022,6,30]]},"abstract":"<jats:p>Background. Myasthenia gravis (MG) is an acquired autoimmune disease. The main clinical features of MG are skeletal muscle fatigue and pathological fatigue, which worsen at night or after fatigue, such as dyspnea, dysphagia, and systemic weakness. Plasma exchange (PE) is often used in patients with acute exacerbation of MG. Intravenous immunoglobulin (IVIG) is a collection of immunoglobulins from thousands of donors. IVIG can replace a variety of immunosuppressants or PE. However, the effect of PE or IVIG on patients\u2019 consciousness, immune function, and prognosis is not clear. Objective. A prospective randomized test of the effects of PE combined with immunoglobulin on consciousness, immune function, and prognosis in patients with myasthenia gravis crisis (MGC). Methods. Sixty patients with MGC treated from February 2019 to April 2021 were enrolled in our hospital. The cases who received PE were set as the PE group, and those who received PE combined with immunoglobulin were set as the PE+immunoglobulin group. The efficacy, clinical score, state of consciousness, immune function, acetylcholine receptor antibody (AChR-Ab), lymphocyte (LYM), albumin (ALB) levels, and the incidence of adverse reactions were compared. Results. The improvement rate was 100.005% in the treatment group and 83.33% in the PE group. After treatment, the clinical score of the PE+immunoglobulin group was lower than that of the PE group, and the clinical relative score of the PE+immunoglobulin group was higher than that of the PE group (<jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>P<\/a:mi>\n                        <a:mo>&lt;<\/a:mo>\n                        <a:mn>0.05<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula>). The number of conscious people in the PE+immunoglobulin group was more than that in the PE group (<jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mi>P<\/c:mi>\n                        <c:mo>&lt;<\/c:mo>\n                        <c:mn>0.05<\/c:mn>\n                     <\/c:math>\n                  <\/jats:inline-formula>). Immunoglobulin A, immunoglobulin M, immunoglobulin G, and immunoglobulin G in the PE+immunoglobulin group were higher than those in the PE group (<jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mi>P<\/e:mi>\n                        <e:mo>&lt;<\/e:mo>\n                        <e:mn>0.05<\/e:mn>\n                     <\/e:math>\n                  <\/jats:inline-formula>). The levels of AChR-Ab and ALB in the PE+immunoglobulin group were higher than those in the PE group, while the level of LYM in the PE+immunoglobulin group was lower than that in the PE group. The incidence of skin system, gastrointestinal system, nervous system, and systemic damage in the PE+immunoglobulin group was lower than that in the PE group (<jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mi>P<\/g:mi>\n                        <g:mo>&lt;<\/g:mo>\n                        <g:mn>0.05<\/g:mn>\n                     <\/g:math>\n                  <\/jats:inline-formula>). Conclusion. The treatment of MGC with PE combined with immunoglobulin can not only effectively enhance the consciousness and immune function of patients but also effectively promote the prognosis, and the safety of treatment can be guaranteed.<\/jats:p>","DOI":"10.1155\/2022\/7796833","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T20:36:01Z","timestamp":1656621361000},"page":"1-7","source":"Crossref","is-referenced-by-count":7,"title":["Effects of Plasma Exchange Combined with Immunoglobulin Therapy on Consciousness, Immune Function, and Prognosis in Patients with Myasthenia Gravis Crisis: A Prospective Randomized Test"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9493-993X","authenticated-orcid":true,"given":"Xu","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Hospital of Changsha, Changsha, Hunan 410005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Bi","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Hospital of Changsha, Changsha, Hunan 410005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Hospital of Changsha, Changsha, Hunan 410005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Hospital of Changsha, Changsha, Hunan 410005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Tao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Hospital of Changsha, Changsha, Hunan 410005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Hospital of Changsha, Changsha, Hunan 410005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Hospital of Changsha, Changsha, Hunan 410005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Rui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Hospital of Changsha, Changsha, Hunan 410005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao-Yang","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Hospital of Changsha, Changsha, Hunan 410005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"issue":"1","key":"1","first-page":"193","article-title":"The feasibility of quantitative MRI of extra-ocular muscles in myasthenia gravis and Graves' orbitopathy","volume":"34","author":"K. R. Keene","year":"2020","journal-title":"NMR in Biomedicine"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1111\/ncn3.12414"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322640"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13546"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00709"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13239"},{"issue":"2","key":"7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of Myasthenia Gravis","volume":"36","author":"C. Farmakidis","year":"2018","journal-title":"Neurologic clinics"},{"issue":"3","key":"8","first-page":"1967","article-title":"Preliminary findings of a dedicated ocular myasthenia gravis rating scale: the OMGRate","volume":"44","author":"S. H. Wong","year":"2020","journal-title":"Neuro-Ophthalmology"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2020.01.047"},{"issue":"5","key":"10","first-page":"441","article-title":"Pseudopartial third nerve palsy as the presenting sign of ocular myasthenia gravis","volume":"97","author":"N. Bertolet Anne","year":"2020","journal-title":"Optometry and Vision Science"},{"issue":"1","key":"11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"N. E. Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116734"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2019.009"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.02.001"},{"issue":"1","key":"15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/nyas.13537","article-title":"Developing treatment guidelines for myasthenia gravis","volume":"1412","author":"D. B. Sanders","year":"2018","journal-title":"Annals of the New York Academy of Sciences"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000004239"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1053\/j.semtcvs.2020.05.005"},{"issue":"1","key":"18","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/WNO.0000000000000814","article-title":"Outcomes after transcervical thymectomy for ocular myasthenia gravis: a retrospective cohort study with inverse probability weighting","volume":"40","author":"A. G. Hamedani","year":"2020","journal-title":"Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2020.e00817"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2020.01.044"},{"issue":"4","key":"21","first-page":"257","article-title":"Treatment of ocular myasthenia gravis","volume":"7","author":"W. T. Cornblath","year":"2020","journal-title":"The Asia-Pacific Journal of Ophthalmology"},{"key":"22","doi-asserted-by":"crossref","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"J. Morren","year":"2020","journal-title":"Journal of the Neurological Sciences"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.08.004"},{"issue":"7","key":"24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14737175.2018.1491310","article-title":"Advances in autoimmune myasthenia gravis management","volume":"18","author":"S. Wang","year":"2018","journal-title":"Expert review of neurotherapeutics"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-019-2289-z"},{"issue":"31","key":"26","first-page":"966","article-title":"Ocular myasthenia gravis: updates on an elusive target","volume":"78","author":"T. Melson Andrew","year":"2019","journal-title":"Current Opinion in Neurology"},{"issue":"1","key":"27","first-page":"913","article-title":"Takotsubo syndrome in patients with myasthenia gravis: a systematic review of previously reported cases","volume":"19","author":"R. Devarajan","year":"2019","journal-title":"BMC Neurology"},{"issue":"2","key":"28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"M. C. Dalakas","year":"2019","journal-title":"Nature Reviews Neurology"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008688"},{"issue":"12","key":"30","first-page":"911","article-title":"Mediastinal hamartoma giving impression of Thymoma in myasthenia gravis patient;Mediastinal hamartoma giving impression of thymoma in myasthenia gravis patient;Mediastinal hamartoma giving impression of thymoma in myasthenia gravis patient","volume":"7","author":"M. \u0130\u015fcan","year":"2019","journal-title":"American Journal of Medical Case Reports"},{"issue":"1","key":"31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"H. Safa","year":"2019","journal-title":"Journal for immunotherapy of cancer"},{"key":"32","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A Practical Approach to Managing Patients With Myasthenia Gravis-Opinions and a Review of the Literature","volume":"11","author":"M. E. Farrugia","year":"2020","journal-title":"Front Neurol"},{"key":"33","doi-asserted-by":"crossref","first-page":"116803","DOI":"10.1016\/j.jns.2020.116803","article-title":"Guidance for the management of myasthenia gravis (MG) and Lambert\u2013Eaton myasthenic syndrome (LEMS) during the COVID\u201319 pandemic","volume":"412","author":"S. Jacob","year":"2020","journal-title":"Journal of the neurological sciences"},{"key":"34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"M. L. Fichtner","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"35","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jca.21694","article-title":"Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status","volume":"34","author":"A. Usmani","year":"2019","journal-title":"Journal of Clinical Apheresis"},{"key":"36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis","volume":"430","author":"G. I. Wolfe","year":"2021","journal-title":"Journal of the Neurological Sciences"},{"issue":"6","key":"37","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11061597","article-title":"Current Treatment of Myasthenia Gravis","volume":"11","author":"M. K. Alhaidar","year":"2022","journal-title":"J Clin Med"},{"issue":"41","key":"38","first-page":"396","article-title":"Autoimmune diseases and conditions - myasthenia gravis; Findings from Cleveland Clinic has provided new information about myasthenia gravis (Myasthenia gravis with muscle-specific tyrosine kinase antibodies: a narrative review)","volume":"67","year":"2018","journal-title":"Biotech Week"},{"issue":"2","key":"39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/practneurol-2019-002336","article-title":"Plasma exchange in neurological disease","volume":"20","author":"C. Osman","year":"2020","journal-title":"Practical Neurology"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13239"},{"key":"41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00324","article-title":"Application of plasma exchange in steroid-responsive encephalopathy","volume":"10","author":"Y. Jiang","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11940-019-0593-y","article-title":"Pediatric Ocular Myasthenia Gravis","volume":"21","author":"K. Fisher","year":"2019","journal-title":"Current Treatment Options in Neurology"}],"updated-by":[{"DOI":"10.1155\/2023\/9786520","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"record-id":"59914"},{"DOI":"10.1155\/2023\/9786520","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000}}],"container-title":["Computational and Mathematical Methods in Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmm\/2022\/7796833.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmm\/2022\/7796833.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmm\/2022\/7796833.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T20:36:29Z","timestamp":1656621389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/cmmm\/2022\/7796833\/"}},"subtitle":[],"editor":[{"given":"Min","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":42,"alternative-id":["7796833","7796833"],"URL":"https:\/\/doi.org\/10.1155\/2022\/7796833","relation":{"retraction":[{"id-type":"doi","id":"10.1155\/2023\/9786520","asserted-by":"object"}]},"ISSN":["1748-6718","1748-670X"],"issn-type":[{"value":"1748-6718","type":"electronic"},{"value":"1748-670X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,30]]}}}